knowledge -WSS

knowledge

author：fashion 2025-09-30 22:04:34 - browse：78444

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： AI can’t replace a physician’s gut feeling

WSS

Medicare Advantage's lean provider networks lead CMS complaints

Data don't support strong claims for Covid

Stopping antidepressants leads to symptoms for 1 in 6 patients

Medicare has a new plan to address drug shortages

UnitedHealth CEO's Medicaid comments send insurer stocks diving

AI can’t replace a physician’s gut feeling

explore

knowledge

focus

Activists slam private health insurers over coverage restrictions

Data don't support strong claims for Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Eli Lilly’s Zepbound improved liver scarring in mid

In Memoriam: Notable people who died in 2023

STAT wants to know your pick for a great summer read or listen

Alkermes shareholders re

ASCO Daily Recap: CAR

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare to cover more brain scans for Alzheimer’s patients

knowledge

Congress needs to close a vaccine

Google and Epic fight stronger regulation of AI in health care

CMS got Medicare Advantage quality rating wrong, judge rules

ASCO Daily Recap: CAR

UnitedHealth CEO's Medicaid comments send insurer stocks diving

STAT wants to know your pick for a great summer read or listen

leisure time

leisure time

hotspot

knowledge